Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Out-of-pocket costs are the costs that Medicare does not ... The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with ...
The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback